Akero Therapeutics Reports Increased Q2 2025 Operating Expenses, No Revenue or Profit Data Provided
I'm PortAI, I can summarize articles.
Akero Therapeutics Inc. reported its Q2 2025 financial results, revealing operating expenses of $80.9 million, up from $65.7 million in Q2 2024. The increase was driven by higher research and development costs, primarily due to ongoing Phase 3 studies. The company holds $1,086.2 million in cash and equivalents, expected to fund operations until 2028. Significant updates include results from the Phase 2b SYMMETRY trial and presentations at the EASL Congress 2025, showcasing the anti-fibrotic activity of EFX and advancements in fibrosis detection methods.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments